



## Curriculum Vitae

Personal information **Ellen van der Schoot**

### Work experience

---

2005-present: Head of the department of Experimental Immunohematology Sanquin Research, Amsterdam, the Netherlands  
2007-present: Professor in Experimental Immunohematology at the Academic Medical centre, University of Amsterdam  
2019-present: Director of the Dutch Cord Blood Bank, Sanquin Research, Amsterdam, the Netherlands  
2000-present: Medical Director of the Laboratory of Cellular Therapies (JACIE-accredited), Sanquin Research, Amsterdam  
2021-2022: Manager Innovation, Sanquin Diagnostics BV  
2012-2020: head of the department of Blood Cell Diagnostics, Sanquin Diagnostics, Amsterdam, the Netherlands  
1991-2005: senior investigator and staff member of the dept. of Experimental Immunohematology (head: prof. dr. D. Roos) of the CLB, Amsterdam;  
1989-2005: head diagnostic sublaboratory Immunocytology, dept. of Experimental Immunohematology; Central Laboratory Blood Transfusion Service (CLB), Amsterdam, the Netherlands.  
1984-1988: PhD student at the department of Immunohematology (CLB, head: prof dr CP Engelfriet) on a project entitled: Immunological characterization of acute myeloid leukemia; funded by KWF (project leader: dr AEG Kr von dem Borne)

### Education and training

---

1977 Gymnasium  $\beta$  Cartesius Lyceum Amsterdam  
1982 Doctoral degree, Medical Faculty University of Amsterdam (with honour)  
1989 Medical Doctor (MD) degree, University of Amsterdam (with honour)  
1989 PhD degree, Immunological characterization of Acute Myeloid Leukemia University of Amsterdam (Promotor prof.dr. CP Engelfriet; co-promotor: dr AEG Kr von dem Borne) (with honour)

### Additional information

---

#### Publications

>300 Publications in peer-reviewed Journals  
H-index (Google Scholar, April 23): 85

#### Projects

Co-promotor or promoter (since 2008) of 42 PhD students

#### Research program:

Main research line is on "Immune response to blood group antigens".  
Alloimmunisation is one of the major side effects of blood transfusion. Furthermore, hemolytic disease of the fetus and newborn (HDFN) and fetal neonatal alloimmune thrombocytopenia (FNAIT) are potentially life threatening diseases caused by the maternal alloantibodies against paternally inherited fetal blood group antigens. We are studying both the antigens, which are the targets of the immune response, and the humoral immune response that leads to cell destruction. This latter line of research occurs within the group of dr. Gestur Vidarsson. The final aim of our research is to develop new diagnostic and preferentially also therapeutic options to further prevent and/or treat allo- or autoimmunization against blood cells.  
In addition we do developmental research on minimal residual disease detection for our diagnostic sublaboratory Immunocytology (proliferative blood diseases). My third line on cellular therapies (in close collaboration with Carlijn Voermans) includes projects focused on

#### Memberships

Founding member of the Blood Group Genomics Consortium (BGC) (2021-present)  
Member of the board of the Worldwide Initiative to eradicate Rh-immune disease (WIRhE) (2019-present)  
International Expert of the research and development Committee of the NHS Blood and Transplant (2012-2021)  
Member of the Working party on Terminology for Red Cell Surface Antigens of the ISBT 2004 - present (now working party on Red Cell Immunogenetics and Blood Group Terminology)  
Member of the Working Party on Molecular Biology of the ISBT 2002-present (now working party on Red Cell Immunogenetics and Blood Group Terminology)  
Member of the NWO-Rubicon Selection committee 2009-2011, NWO-Veni committee 2014-2015, NWO-Vici Selection committee 2016-2020  
Member of the Scientific Advisory council of the Landsteiner Foundation on Transfusion Research (LSBR) (2016-2021)  
Scientific Secretary of the International Society of Blood Transfusion June 2014 – June 2018  
Congress President of the 23rd Regional Congress of the ISBT, June 2013, Amsterdam, the Netherlands  
Member of the Scientific Committee of the 14th, 15th and 16th Annual Congresses of the European Hematology Association (2009-2011)  
Member of the Scientific Advisory Committee of Sanquin 2007-2011  
Member of the Steering Committee of 6th FR- EU project SAFE (2004-2009) (non-invasive prenatal diagnosis; a project with 49 partners from 19 countries and a budget of 12 million Euro)  
Section organizer of the Red cell section of the 7th Human Workshop on Leukocyte Differentiation Antigens (HLDA) held in Harrogate, UK June 2000  
Member of the board of the Dutch Platform on Molecular Diagnostics of Hematological Malignancies (1998-2006)  
Founder of the Dutch Foundation on Immuno Hemato Oncology Diagnostics and member of the board from 1991-

1998

#### Other Relevant Information

Scientific prizes/awards:

2023: Rise award for best article in Transfusion. American Association of Blood Banks

2023: Rise award for best article in Transfusion. American Association of Blood Banks

2019: James Blundell award, British Blood Transfusion Society

2019: ISBT award , International Society of Blood Transfusion

2016: Hogman award, Swedish Society of Clinical Immunology and Transfusion Medicine.

2016: Rise award for best article in Transfusion. American Association of Blood Banks